Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Takeda Pharmaceutical Co Ltd's new investigational drug Vedolizumab entered phase 3 clinical trials in Japan for the treatment of Ulcerative Colitis and Crohn's Disease


Wednesday, 8 Jan 2014 01:15am EST 

Takeda Pharmaceutical Co Ltd:Says vedolizumab (development code: MLN0002), an investigational drug for the treatment of moderate and severe ulcerative colitis (UC) and Crohn's disease (CD), has entered into two new phase three clinical trials in Japan.Says clinical trials are both placebo-controlled, multicenter, randomized, double-blind, parallel-group studies designed to evaluate the efficacy, safety and pharmacokinetics of vedolizumab as an induction and maintenance therapy for ulcerative colitis and Crohn's disease.says primary endpoints include clinical response at the 10th week (induction phase), and clinical remission after 60 weeks (maintenance phase). 

Company Quote

4470.5
133.0 +3.07%
20 Oct 2014